Mass spectrometry use in chronic kidney disease study
Link between cardiovascular mortality and chronic kidney disease has been studied.

HPLC, UHPLC

Mass spectrometry use in chronic kidney disease study

17 May, 2011

Published over 15 years ago. See the latest and most current information on HPLC, UHPLC.

Mass spectrometry has been used to study the increase of cardiovascular mortality among patients with chronic kidney disease (CKD).

The study, published by Proteome Science, stated that although a link between atherosclerosis, which is a major cause of cardiovascular mortality, and kidney dysfunction is undeniable, the factors enhancing CKD-mediated plaque formation are not fully understood.

To increase the awareness of formation, a team of scientists including Magdalena Luczak, Dorota Formanowicz, Elzbieta Pawliczak, Maria Wanic-Kossowska, Andrzej Wykretowicz and Marek Figlerowic carried out a comparative proteomic analysis of blood plasma proteins isolated from 75 patients in assorted stages of renal dysfunction (CKD group), 25 patients with advanced cardiovascular disease (CVD group) and 25 healthy volunteers (HV group).

With the use of mass spectrometry, the study revealed that there are at least two different processes that contribute to plaque formation in CKD- and CVD-mediated atherosclerosis, with a more intense inflammatory process seen in CKD patients.

However, it also suggested that there are notable differences in the effectiveness of cholesterol transport in both patient groups. 

Latest News

Explore Our Other Sites

Labmate Online
Lab-grown kidney organoids set to recast research landscape into kidney disease
Explore more Arrow
Envirotech Online
EU ETS benchmark update puts industrial emissions data under sharper scrutiny
Explore more Arrow
Pollution Solutions Online
Next-generation reverse osmosis membranes for more efficient and cost-effective seawater desalination
Explore more Arrow
Petro Online
New test method ASTM D8606 has been officially released
Explore more Arrow